Big Move in Autoimmune Space: Aurinia to Buy Kezar Life Sciences
Aurinia Pharmaceuticals has agreed to acquire Kezar Life Sciences for $6.955 in cash per share plus a Contingent Value Right (CVR).
/ 10 items
#XY Event-Driven Stocks↓
Game-Changer for IPF: Inhaled Tyvaso Preserves Lung Function in Major TETON-1 Study
The United Therapeutics TETON-1 trial shows that inhaled Tyvaso preserves lung function by 130 mL versus placebo and reduces disease progression. Positive results were seen across all patient groups, with an FDA filing planned for this summer.
Viridian’s Elegrobart Data: Promising Proptosis Win, But Missing the Full Picture for Thyroid Eye Disease
Viridian highlights 54% proptosis response for Elegrobart in TED, but secondary endpoints like inflammation and diplopia showed limited gains.
FDA Fast-Tracks Zymeworks’ New Ovarian Cancer Drug ZW191
Zymeworks receives U.S. FDA Fast Track Designation for ZW191, its FRα-targeting antibody-drug conjugate for advanced platinum-resistant ovarian cancer.